Leptomeningeal metastases from small cell lung cancer responsive to temozolomide therapy

Journal of Thoracic Oncology

Volumn 5, Issue 10, 2010, Pages 1716-1717

  Zauderer, Marjorie ^a   Krug, Lee M ^a   Pietanza, M Catherine ^a   O'Rourke, Denise ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CARBOPLATIN; CISPLATIN; ETOPOSIDE; TEMOZOLOMIDE;

ADULT; ANTINEOPLASTIC ACTIVITY; BRAIN METASTASIS; BRONCHUS OBSTRUCTION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LETTER; LUNG SMALL CELL CANCER; MALE; MENINGEAL METASTASIS; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANEOPLASTIC NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; SYMPTOM; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77958187979     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181f1cc32     Document Type: Letter

References (3)

1. Seute T, Leffers P, ten Velde GP, et al. Leptomeningeal metastases from small cell lung carcinoma. Cancer 2005;104:1700-1705.
2. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002; 20:2388-2399. (Pubitemid 34441669)
3. Pietanza MC, Periera L, Dunne M, et al. Phase II study of temozolomide for relapsed sensitive or refractory small cell lung cancer. J Thorac Oncol 2009;4:S819.